You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 8, 2025

New Draft Regulatory Framework for Food Product Declaration and Registration in Vietnam

Subscribe to Updates

In response to persistent challenges in food safety management and recent high-profile incidents involving counterfeit supplemented foods, infant formula, and health supplements, the Ministry of Health of Vietnam is initiating comprehensive regulatory reforms. These reforms include proposed amendments to the Law on Food Safety and its implementing Decree No. 15/2018/ND-CP (Decree 15), introducing significant changes to the registration procedures for food products, especially supplemented food products and health supplements.

While awaiting public consultation and approval of the amended Law on Food Safety, the Ministry of Health is developing an interim mechanism, which includes a draft decree to replace Decree 15 and a draft resolution to address urgent issues until the amended law becomes effective, expected in July 2026.

To align with the new Law on Quality of Products and Goods, the draft resolution stipulates that the declaration and registration of food products will follow the following procedures:

  • Declaration of applied standards for food products, which is currently known as the “self-declaration” procedure, applies to processed packaged foods, food additives, food processing aids, containers or utensils that come into direct contact with food, packaging materials in direct contact with food, and micronutrients.
  • Granting of circulation numbers, which is the current “registration of product declaration” procedure, applies to specific categories of food including health supplements, medical nutrition foods, special dietary foods, nutritional products for children up to 36 months, and, especially, supplemented foods, which are currently subject to self-declaration but will be shifted to this registration procedure.

In addition, the following new procedure is introduced in the draft decree:

  • Registration of declaration of conformity, which applies to the same product category as in “declaration of applied standards” above, but is for products that are already subject to technical regulations covering both safety indicators and quality indicators.

Changes to the Food Product Declaration and Registration Procedures

Details of the procedures for declaration of applied standards and granting of circulation numbers are stipulated in the draft resolution, while details of the procedure for registration of declaration of conformity are stipulated in the draft decree. These procedures will see some key changes compared to the current regulations, as highlighted below:

  • Letter of authorization: A letter of authorization (LOA) from the manufacturer or product owner to the entity conducting the declaration of applied standard or registration is a new requirement applicable to both procedures. Information that must be included in the LOA is detailed in the draft resolution.
  • Quality criteria: It is newly required to test quality criteria in a Certificate of Analysis (COA), in addition to safety criteria, for both procedures. The COA will need to follow the format set out in the draft resolution.
  • Declaration of conformity with internal standards: In addition to the declaration of compliance with food safety requirements, both product declaration and registration procedures have a new requirement that the declaring or registering entity must confirm that the product complies with its internal standards. This conformity is substantiated by submitting the in-house specification along with a dossier detailing the development of the specification.
  • Timeline for declaration of applied standards: The draft resolution introduces a defined principal evaluation timeline of 21 days from the date of submission—an element not specified under current regulations. It also clarifies that entities may begin manufacturing and trading declared products once the declaration, including the entity name and product name, is published on the authority’s official website.
  • Required documents: The required documents applicable to products subject to the registration of product declaration procedure are much more stringent than in current practice. The registration dossier will cover two parts: (i) administrative and (ii) technical. More technical documents will be required for the technical part, such as a manufacturer’s certificate (GMP, HACCP, etc.), report on product research and development process, documentation on quality and safety standards, documentation of manufacturing process, long-term stability report, and other technical explanation (if necessary).
  • Timeline for registration of product declaration: The estimated principal approval timeline is specifically set as 90 days from the date of submission. Compared to the current regulation, the timeline for submitting a supplemental dossier will be reduced from 90 working days to 60 working days from the date of receiving an official notice of deficiency. Notably, instead of an unlimited number of revisions, the draft resolution only permits a one-time revision.
  • Exclusion of certain products from the registration of product declaration procedure: Certain food additives—including blended food additives with new functions, those not on the Ministry of Health’s permitted list, or those used for incorrect purposes—are no longer subject to the registration of product declaration procedure under the draft resolution. Neither the draft resolution nor the draft decree specify how these products should be registered, suggesting that future regulations on food additive management may address this gap.

Suspension of Product Declaration Registration

The draft resolution introduces a new provision allowing competent authorities to temporarily suspend the receipt and processing of product declaration dossiers from entities who have violated food safety regulations. Processing will resume once the violations are fully remedied and a compliance report is submitted.

Transitional Provision

Under the draft decree, for food products that are registered or self-declared before the effective date of the decree, product owners must complete the procedures for re-registering or re-declaring product standards in accordance with the draft resolution (after it is enacted), within the following timeframes:

  • 18 months from the effective date of the decree for products that already have a Certificate of Receipt for Product Declaration.
  • 6 months from the effective date of the decree for products that are self-declared.

After these deadlines, any previous product declaration documents or certificates will no longer be valid for production or importation. However, products with a certificate that were produced within 18 months of the decree’s effective date and products that were self-declared and produced within 6 months of the decree’s effective date may continue to be circulated until their expiration date, and the product owner remains fully responsible for those products.

The draft decree does not specify a transitional period for the supplemented food products that will be shifted from the self-declaration procedure to the registration of product declaration procedure.

The draft resolution and draft decree will be discussed and approved under the fast-track procedure. However, no expected effective date has been provided. It remains possible that further revisions to the draft decree may be introduced.

Impact for Businesses and Next Steps

Businesses will be required to prepare additional documentation for declaration and registration processes to comply with the new regulations once they are enacted. Stricter documentation will be required for products subject to registration of declaration procedure, especially for supplemented foods, which are shifted from self-declaration procedure to registration of product declaration procedure.

Businesses should review their product portfolios to determine applicable registration pathways, develop plans to update the declaration and registration dossiers, and monitor for further amendment, official issuance, and implementation guidance.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 31, 2024
On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025. Contents of Circular 12 The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements. Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation. Transitional Provisions Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning. Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission. From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.
Read More
June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
Read More
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU
Read More
February 14, 2024
Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA
Read More